Cargando…

Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma

BACKGROUND: Glioma is the most common malignant primary brain tumor and is characterized by a poor prognosis and limited therapeutic options. ISG20 expression is induced by interferons or double-stranded RNA and is associated with poor prognosis in several malignant tumors. Nevertheless, the express...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Yaojun, Liu, Hongyu, Wu, Qiyan, Wang, Lingxiong, Yu, Yanju, Yin, Fan, Feng, Cong, Ren, Xuewen, Liu, Tianyi, Chen, Ling, Zhu, Haiyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303331/
https://www.ncbi.nlm.nih.gov/pubmed/37380984
http://dx.doi.org/10.1186/s12885-023-11057-0
_version_ 1785065252846567424
author Peng, Yaojun
Liu, Hongyu
Wu, Qiyan
Wang, Lingxiong
Yu, Yanju
Yin, Fan
Feng, Cong
Ren, Xuewen
Liu, Tianyi
Chen, Ling
Zhu, Haiyan
author_facet Peng, Yaojun
Liu, Hongyu
Wu, Qiyan
Wang, Lingxiong
Yu, Yanju
Yin, Fan
Feng, Cong
Ren, Xuewen
Liu, Tianyi
Chen, Ling
Zhu, Haiyan
author_sort Peng, Yaojun
collection PubMed
description BACKGROUND: Glioma is the most common malignant primary brain tumor and is characterized by a poor prognosis and limited therapeutic options. ISG20 expression is induced by interferons or double-stranded RNA and is associated with poor prognosis in several malignant tumors. Nevertheless, the expression of ISG20 in gliomas, its impact on patient prognosis, and its role in the tumor immune microenvironment have not been fully elucidated. METHODS: Using bioinformatics, we comprehensively illustrated the potential function of ISG20, its predictive value in stratifying clinical prognosis, and its association with immunological characteristics in gliomas. We also confirmed the expression pattern of ISG20 in glioma patient samples by immunohistochemistry and immunofluorescence staining. RESULTS: ISG20 mRNA expression was higher in glioma tissues than in normal tissues. Data-driven results showed that a high level of ISG20 expression predicted an unfavorable clinical outcome in glioma patients, and revealed that ISG20 was possibly expressed on tumor-associated macrophages and was significantly associated with immune regulatory processes, as evidenced by its positive correlation with the infiltration of regulatory immune cells (e.g., M2 macrophages and regulatory T cells), expression of immune checkpoint molecules, and effectiveness of immune checkpoint blockade therapy. Furthermore, immunohistochemistry staining confirmed the enhanced expression of ISG20 in glioma tissues with a higher WHO grade, and immunofluorescence assay verified its cellular localization on M2 macrophages. CONCLUSIONS: ISG20 is expressed on M2 macrophages, and can serve as a novel indicator for predicting the malignant phenotype and clinical prognosis in glioma patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11057-0.
format Online
Article
Text
id pubmed-10303331
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103033312023-06-29 Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma Peng, Yaojun Liu, Hongyu Wu, Qiyan Wang, Lingxiong Yu, Yanju Yin, Fan Feng, Cong Ren, Xuewen Liu, Tianyi Chen, Ling Zhu, Haiyan BMC Cancer Research BACKGROUND: Glioma is the most common malignant primary brain tumor and is characterized by a poor prognosis and limited therapeutic options. ISG20 expression is induced by interferons or double-stranded RNA and is associated with poor prognosis in several malignant tumors. Nevertheless, the expression of ISG20 in gliomas, its impact on patient prognosis, and its role in the tumor immune microenvironment have not been fully elucidated. METHODS: Using bioinformatics, we comprehensively illustrated the potential function of ISG20, its predictive value in stratifying clinical prognosis, and its association with immunological characteristics in gliomas. We also confirmed the expression pattern of ISG20 in glioma patient samples by immunohistochemistry and immunofluorescence staining. RESULTS: ISG20 mRNA expression was higher in glioma tissues than in normal tissues. Data-driven results showed that a high level of ISG20 expression predicted an unfavorable clinical outcome in glioma patients, and revealed that ISG20 was possibly expressed on tumor-associated macrophages and was significantly associated with immune regulatory processes, as evidenced by its positive correlation with the infiltration of regulatory immune cells (e.g., M2 macrophages and regulatory T cells), expression of immune checkpoint molecules, and effectiveness of immune checkpoint blockade therapy. Furthermore, immunohistochemistry staining confirmed the enhanced expression of ISG20 in glioma tissues with a higher WHO grade, and immunofluorescence assay verified its cellular localization on M2 macrophages. CONCLUSIONS: ISG20 is expressed on M2 macrophages, and can serve as a novel indicator for predicting the malignant phenotype and clinical prognosis in glioma patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11057-0. BioMed Central 2023-06-28 /pmc/articles/PMC10303331/ /pubmed/37380984 http://dx.doi.org/10.1186/s12885-023-11057-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Peng, Yaojun
Liu, Hongyu
Wu, Qiyan
Wang, Lingxiong
Yu, Yanju
Yin, Fan
Feng, Cong
Ren, Xuewen
Liu, Tianyi
Chen, Ling
Zhu, Haiyan
Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma
title Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma
title_full Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma
title_fullStr Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma
title_full_unstemmed Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma
title_short Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma
title_sort integrated bioinformatics analysis and experimental validation reveal isg20 as a novel prognostic indicator expressed on m2 macrophage in glioma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303331/
https://www.ncbi.nlm.nih.gov/pubmed/37380984
http://dx.doi.org/10.1186/s12885-023-11057-0
work_keys_str_mv AT pengyaojun integratedbioinformaticsanalysisandexperimentalvalidationrevealisg20asanovelprognosticindicatorexpressedonm2macrophageinglioma
AT liuhongyu integratedbioinformaticsanalysisandexperimentalvalidationrevealisg20asanovelprognosticindicatorexpressedonm2macrophageinglioma
AT wuqiyan integratedbioinformaticsanalysisandexperimentalvalidationrevealisg20asanovelprognosticindicatorexpressedonm2macrophageinglioma
AT wanglingxiong integratedbioinformaticsanalysisandexperimentalvalidationrevealisg20asanovelprognosticindicatorexpressedonm2macrophageinglioma
AT yuyanju integratedbioinformaticsanalysisandexperimentalvalidationrevealisg20asanovelprognosticindicatorexpressedonm2macrophageinglioma
AT yinfan integratedbioinformaticsanalysisandexperimentalvalidationrevealisg20asanovelprognosticindicatorexpressedonm2macrophageinglioma
AT fengcong integratedbioinformaticsanalysisandexperimentalvalidationrevealisg20asanovelprognosticindicatorexpressedonm2macrophageinglioma
AT renxuewen integratedbioinformaticsanalysisandexperimentalvalidationrevealisg20asanovelprognosticindicatorexpressedonm2macrophageinglioma
AT liutianyi integratedbioinformaticsanalysisandexperimentalvalidationrevealisg20asanovelprognosticindicatorexpressedonm2macrophageinglioma
AT chenling integratedbioinformaticsanalysisandexperimentalvalidationrevealisg20asanovelprognosticindicatorexpressedonm2macrophageinglioma
AT zhuhaiyan integratedbioinformaticsanalysisandexperimentalvalidationrevealisg20asanovelprognosticindicatorexpressedonm2macrophageinglioma